<DOC>
	<DOCNO>NCT02627768</DOCNO>
	<brief_summary>The purpose study evaluate treatment retention psoriatic arthritis participant STELARA tumor necrosis factor alpha inhibitor ( TNFi ) therapies relation effectiveness , safety , benefit/risk examine clinical response .</brief_summary>
	<brief_title>A Study Assessment STELARA Tumor Necrosis Factor Alpha Inhibitor Therapies Participants With Psoriatic Arthritis</brief_title>
	<detailed_description>This prospective , observational , cohort study collect data adult participant confirm diagnosis psoriatic arthritis ( PsA ) start STELARA TNFi first , second , third line biologic disease-modifying antirheumatic drug ( bDMARD ) therapy . Approximately 1,400 participant enrol study , 700 participant receive STELARA study entry 700 participant receive TNFi therapy study entry . Recruitment study continue 2 year , 3-year follow-up period . For participant , follow-up period continue maximum 3 year ( 36 month ) inclusion study . Participants primarily assess parameter treatment retention , clinical response , effectiveness safety observational period 36 month .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Must confirm diagnosis psoriatic arthritis ( PsA ) determine rheumatologist accord ClASsification criterion Psoriatic Arthritis ( CASPAR ) criterion Must start STELARA approve tumor necrosis factor alpha inhibitor ( TNFi ) ( include TNFi biosimilar ) first , second third line biologic diseasemodifying antirheumatic drug ( bDMARD ) therapy PsA time enrollment observational study within maximum 1month window baseline visit Must sign participation agreement/informed consent form ( ICF ) allow data collection source data verification accordance local requirement Participant start STELARA TNFi therapy fourth line biologic treatment Participant unwilling unable participate longterm data collection Participant receive investigational drug ( include investigational vaccine ) use invasive investigational medical device within 30 day start study first data collection time point Participant currently enrol interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>STELARA</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Ustekinumab</keyword>
</DOC>